Longeveron Inc(LGVN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LGVN Longeveron Inc

交易中 09-24 14:53:30 EDT

2.81

+0.21

+8.08%

最高2.82	最低2.50	成交量11.19万
今开2.54	昨收2.60	日振幅12.31%
总市值887.90万	流通市值765.87万	总股本315.98万
成交额30.18万	换手率4.11%	流通股本272.55万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LGVN","market":"US","secType":"STK","nameCN":"Longeveron Inc","latestPrice":2.81,"timestamp":1790275991827,"preClose":2.6,"halted":0,"volume":111929,"delay":0,"changeRate":0.08076923076923075,"floatShares":2725530,"shares":3159795,"eps":-10,"marketStatus":"交易中","change":0.21,"latestTime":"09-24 14:53:30 EDT","open":2.54,"high":2.82,"low":2.5,"amount":301839.0014574,"amplitude":0.123077,"askPrice":2.81,"askSize":663,"bidPrice":2.8,"bidSize":4489,"shortable":3,"etf":0,"ttmEps":-10,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790280000000},"marketStatusCode":2,"adr":0,"listingDate":1613106000000,"exchange":"NASDAQ","adjPreClose":2.6,"preHourTrading":{"tag":"盘前","latestPrice":2.56,"preClose":2.6,"latestTime":"09:06 EDT","volume":840,"amount":2164.0783079999997,"timestamp":1790255184656,"change":-0.04,"changeRate":-0.015385,"amplitude":0.060192},"postHourTrading":{"tag":"盘后","latestPrice":2.5658,"preClose":2.6,"latestTime":"19:53 EDT","volume":2030,"amount":5191.8758,"timestamp":1790207631804,"change":-0.0342,"changeRate":-0.013154,"amplitude":0.027692},"volumeRatio":0.276277},"requestUrl":"/m/hq/s/LGVN","defaultTab":"news","newsList":[{"id":"1189014002","title":"Longeveron计划寻求融资渠道及其他潜在收入机会，以推进Laromestrocel在长寿及衰老相关虚弱症领域的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=1189014002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189014002?lang=zh_cn&edition=full","pubTime":"2026-09-17 05:30","pubTimestamp":1789594209,"startTime":"0","endTime":"0","summary":"Longeveron公司宣布，其战略重点在于开拓多元化的资金来源以及探索其他潜在的收益途径，旨在全力推动其在长寿科学及衰老相关虚弱症治疗方面的核心候选药物Laromestrocel向前发展。此举彰显了该公司对这一新兴治疗领域长期投入的决心，并试图通过更广泛的财务策略来支撑其研发管线。该公司正积极评估各种选项，以确保这一备受瞩目的项目能获得充足的资源，从而加速其临床进程和商业化可能性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183151807","title":"Longeveron公布Laromestrocel治疗左心发育不全综合征的ELPIS II 2B期临床试验顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1183151807","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183151807?lang=zh_cn&edition=full","pubTime":"2026-09-17 05:28","pubTimestamp":1789594116,"startTime":"0","endTime":"0","summary":"Longeveron公司今日宣布，其评估Laromestrocel作为左心发育不全综合征（HLHS）潜在治疗方案的ELPIS II 2B期临床试验已获得顶线结果。这一里程碑式的数据公布，为该公司在再生医学领域的布局增添了关键一笔。备受关注的ELPIS II研究，其最终揭晓的数据或将为这一罕见先天性心脏病患者群体带来新的曙光。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120415254","title":"Longeveron第二季度每股亏损0.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1120415254","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120415254?lang=zh_cn&edition=full","pubTime":"2026-08-13 04:24","pubTimestamp":1786566275,"startTime":"0","endTime":"0","summary":"美国生物科技公司Longeveron Inc（股票代码：LGVN）于8月12日披露了其第二季度财务数据。该季度运营支出达到635.3万美元，而每股收益则录得-0.19美元。这一数字揭示了公司在研发及运营方面的持续投入情况。尽管Longeveron目前尚未实现盈利，但其在再生医学领域的探索仍在持续推进，尤其针对衰老相关疾病的研究。投资者需密切关注其未来现金流表现及管线进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102716014","title":"Longeveron获欧洲药品管理局授予中小企业资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1102716014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102716014?lang=zh_cn&edition=full","pubTime":"2026-06-09 21:22","pubTimestamp":1781011357,"startTime":"0","endTime":"0","summary":"Longeveron Inc 已成功获得欧洲药品管理局（EMA）授予的中小企业（SME）资格。这一认定标志着公司在欧洲监管框架内获得了重要的官方身份认可，有望为其在欧洲市场的研发与商业化活动带来实质性支持与便利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148764017","title":"Longeveron致股东信：阐述公司战略、合作路径及2026年核心任务","url":"https://stock-news.laohu8.com/highlight/detail?id=1148764017","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148764017?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:07","pubTimestamp":1779307636,"startTime":"0","endTime":"0","summary":"Longeveron Inc向股东发布公开信，详细阐述了公司的核心战略框架、战略合作模式以及为2026年设定的关键发展目标。信件重点说明了公司推进业务增长与创造长期价值的规划路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158339007","title":"Longeveron宣布独立数据监察委员会正面审阅并建议完成针对左心发育不全综合征的2B期干细胞疗法临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1158339007","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158339007?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:10","pubTimestamp":1778505015,"startTime":"0","endTime":"0","summary":"Longeveron Inc宣布，其独立数据监察委员会已完成对一项针对左心发育不全综合征（HLHS）的2B期干细胞疗法临床试验的中期数据审阅。委员会审阅后给出了正面意见，并建议公司按计划完成该项临床试验。\n此项临床试验旨在评估Longeveron的干细胞疗法对HLHS患儿的治疗效果与安全性。独立数据监察委员会的审阅结论为试验的继续进行提供了支持，标志着该疗法在关键开发阶段取得了积极进展。公司表示将遵循委员会的建议，持续推进试验直至完成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178616204","title":"Longeveron与美国FDA召开建设性C类会议，为Elpis II期2B临床试验数据揭晓铺路，该试验评估左心发育不全综合征疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1178616204","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178616204?lang=zh_cn&edition=full","pubTime":"2026-05-09 04:07","pubTimestamp":1778270843,"startTime":"0","endTime":"0","summary":"在备受期待的Elpis II期2B临床试验数据揭晓之前，Longeveron Inc宣布与美国食品药品监督管理局（FDA）成功举行了一次建设性的C类会议。此次会议的核心议题，是评估针对左心发育不全综合征（HLHS）的潜在疗法。\n这次及时的沟通，为公司未来与监管机构的互动奠定了积极基调。会议聚焦于即将到来的临床试验数据，为后续可能的监管提交路径进行了初步探讨。对于关注HLHS这一复杂先天性心脏病治疗进展的投资者和医学界而言，此举标志着研发进程中的一个重要节点。\n随着数据读出的临近，此次与FDA的建设性对话，有望为Longeveron在该关键领域的后续开发策略提供清晰指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274562","title":"Longeveron Inc.盘中异动 股价大跌5.30%报1.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518274562?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:45","pubTimestamp":1741617931,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时45分，Longeveron Inc.股票出现波动，股价快速跳水5.30%。截至发稿，该股报1.43美元/股，成交量4.4991万股，换手率0.30%，振幅4.64%。Longeveron Inc.股票所在的生物技术行业中，整体跌幅为0.06%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3490.20%、767.40%、665.59%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.34%、41.36%、40.33%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224531964047d0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310224531964047d0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518442576","title":"Longeveron Inc.2024财年实现净利润-15.97百万美元，同比增加25.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518442576","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518442576?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:00","pubTimestamp":1741449657,"startTime":"0","endTime":"0","summary":"3月9日，Longeveron Inc.公布财报，公告显示公司2024财年净利润为-15.97百万美元，同比增加25.41%；其中营业收入为2.39百万美元，同比增加237.09%，每股基本收益为-2.62美元。从资产负债表来看，Longeveron Inc.总负债3.67百万美元，其中短期债务623000.00美元，资产负债比为6.97，流动比率为7.61。机构评级：截至2025年3月9日，当前有3家机构对Longeveron Inc.目标价做出预测，其中目标均价为8.67美元，其中最低目标价为6.00美元，最高目标价为10.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000213abef97de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000213abef97de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517492596","title":"Longeveron Inc.盘中异动 下午盘大幅上涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517492596","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517492596?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:38","pubTimestamp":1741203486,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时38分，Longeveron Inc.股票出现异动，股价快速拉升5.26%。截至发稿，该股报1.40美元/股，成交量8.823万股，换手率0.59%，振幅6.02%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为2.02%。Longeveron Inc.公司简介：Longeveron Inc 是一家处于临床阶段的生物技术公司，致力于开发再生药物，以满足与衰老相关和危及生命的特殊疾病方面尚未得到满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306033807abea0714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306033807abea0714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516342136","title":"Longeveron Inc.盘中异动 股价大涨8.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516342136","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516342136?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:32","pubTimestamp":1741012364,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时32分，Longeveron Inc.股票出现波动，股价大幅拉升8.55%。截至发稿，该股报1.65美元/股，成交量108.495万股，换手率7.31%，振幅4.61%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.42%、27.27%、22.55%，振幅较大的相关个股有Entero Therapeutics Inc.、Spruce Biosciences, Inc.、Cibus, Inc.，振幅分别为21.22%、19.25%、9.55%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223244a25d401b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223244a25d401b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516334302","title":"Longeveron(LGVN.US)：2024年Q4财报实现营收60.3万美元，前值为6.3万美元，预期值为66万美元；每股收益为-0.27美元，前值为-2.50美元，预期值为-0.36美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516334302","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516334302?lang=zh_cn&edition=full","pubTime":"2025-03-01 05:36","pubTimestamp":1740778585,"startTime":"0","endTime":"0","summary":"Longeveron(LGVN.US)：2024年Q4财报实现营收60.3万美元，前值为6.3万美元，预期值为66万美元；每股收益为-0.27美元，前值为-2.50美元，预期值为-0.36美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01053648470332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195717291","title":"Longeveron 2024财年GAAP每股收益$(2.62)优于预期$(3.53)，销售额$239.2万优于预期$214.3万","url":"https://stock-news.laohu8.com/highlight/detail?id=1195717291","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195717291?lang=zh_cn&edition=full","pubTime":"2025-03-01 05:14","pubTimestamp":1740777251,"startTime":"0","endTime":"0","summary":"Longeveron报告的季度每股亏损为$，优于分析师一致预期的$，超出25.78%。以上内容来自Benzinga Earnings专栏，原文如下：Longeveron  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 25.78 percent. The company reported quarterly sales of $2.392 million which beat the analyst consensus estimate of $2.143 million by 11.63 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Longeveron 2024财年GAAP每股收益$(2.62)优于预期$(3.53)，销售额$239.2万优于预期$214.3万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320774","title":"Longeveron Inc.盘中异动 大幅下挫5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320774","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320774?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:35","pubTimestamp":1740753314,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时35分，Longeveron Inc.股票出现波动，股价大幅下跌5.13%。截至发稿，该股报1.45美元/股，成交量8331股，换手率0.06%，振幅3.92%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.16%。其相关个股中，Enveric Biosciences, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 、Virpax Pharmaceuticals, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为490.03%、248.25%、138.01%，振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Enveric Biosciences, Inc.、Anaptysbio, Inc.，振幅分别为31.14%、24.53%、16.10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223514abe0ebc6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223514abe0ebc6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513778627","title":"Longeveron Inc.盘中异动 早盘大幅下挫5.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513778627","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513778627?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:08","pubTimestamp":1740409701,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时08分，Longeveron Inc.股票出现异动，股价快速下跌5.13%。截至发稿，该股报1.48美元/股，成交量4.3846万股，换手率0.30%，振幅4.81%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.64%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为166.64%、73.09%、26.03%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、42.86%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230821a2521dbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230821a2521dbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513215760","title":"Longeveron Inc.盘中异动 下午盘股价大跌5.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513215760","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513215760?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:22","pubTimestamp":1740162140,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时22分，Longeveron Inc.股票出现波动，股价急速下挫5.79%。截至发稿，该股报1.55美元/股，成交量7.2035万股，换手率0.49%，振幅6.09%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.42%。Longeveron Inc.公司简介：Longeveron Inc 是一家处于临床阶段的生物技术公司，致力于开发再生药物，以满足与衰老相关和危及生命的特殊疾病方面尚未得到满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222022220962baf1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222022220962baf1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512916597","title":"Longeveron Inc.盘中异动 早盘股价大涨9.58%报1.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512916597","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2512916597?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:30","pubTimestamp":1739889048,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时30分，Longeveron Inc.股票出现波动，股价快速拉升9.58%。截至发稿，该股报1.83美元/股，成交量16.0387万股，换手率1.08%，振幅0.00%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Longeveron Inc.公司简介：Longeveron Inc 是一家处于临床阶段的生物技术公司，致力于开发再生药物，以满足与衰老相关和危及生命的特殊疾病方面尚未得到满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223049abd3aeb4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218223049abd3aeb4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508014945","title":"Longeveron Inc.盘中异动 快速跳水6.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508014945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508014945?lang=zh_cn&edition=full","pubTime":"2025-02-03 22:32","pubTimestamp":1738593149,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日22时32分，Longeveron Inc.股票出现波动，股价大幅跳水6.17%。截至发稿，该股报1.45美元/股，成交量2.1482万股，换手率0.14%，振幅0.00%。Longeveron Inc.股票所在的生物技术行业中，整体跌幅为0.51%。其相关个股中，Hcw Biologics Inc.、Gh Research Plc、Briacell Therapeutics Corp.涨幅较大，Hcw Biologics Inc.、Briacell Therapeutics Corp.、Cyclerion Therapeutics, Inc.较为活跃，换手率分别为315.15%、216.73%、126.38%，振幅较大的相关个股有Hcw Biologics Inc.、Briacell Therapeutics Corp.、Briacell Therapeutics Corp C/Wts 24/02/2025，振幅分别为14.27%、12.85%、12.28%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032232299616fb84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502032232299616fb84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508969329","title":"Longeveron Inc.盘中异动 股价大跌5.00%报1.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508969329","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508969329?lang=zh_cn&edition=full","pubTime":"2025-02-01 02:39","pubTimestamp":1738348758,"startTime":"0","endTime":"0","summary":"北京时间2025年02月01日02时39分，Longeveron Inc.股票出现波动，股价大幅下挫5.00%。截至发稿，该股报1.52美元/股，成交量14.0133万股，换手率0.94%，振幅7.50%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.83%。其相关个股中，180 Life Sciences Corp C/Wts 07/11/2025、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Metsera, Inc.涨幅较大，Cyclerion Therapeutics, Inc.、Nls Pharmaceutics Ltd.、Silexion Therapeutics Corp较为活跃，换手率分别为2717.89%、2011.00%、197.87%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Cyclerion Therapeutics, Inc.，振幅分别为98.89%、80.00%、56.30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201023918961507ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250201023918961507ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LGVN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507460847","title":"Longeveron Inc.盘中异动 临近收盘大幅拉升5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507460847","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507460847?lang=zh_cn&edition=full","pubTime":"2025-01-31 04:59","pubTimestamp":1738270791,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日04时59分，Longeveron Inc.股票出现波动，股价大幅拉升5.19%。截至发稿，该股报1.62美元/股，成交量7.3963万股，换手率0.50%，振幅5.19%。Longeveron Inc.股票所在的生物技术行业中，整体涨幅为0.06%。其相关个股中，Tectonic Therapeutic, Inc.、Dominari Holdings Inc.、Alterity Therapeutics Limited涨幅较大，Kazia Therapeutics Limited、Silexion Therapeutics Corp、Alterity Therapeutics Limited较为活跃，换手率分别为1847.73%、346.63%、259.83%，振幅较大的相关个股有Dominari Holdings Inc.、Cero Therapeutics Holdings, Inc.、Kazia Therapeutics Limited，振幅分别为70.55%、65.98%、65.94%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131045951a2349530&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131045951a2349530&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LGVN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.longeveron.com","stockEarnings":[{"period":"1week","weight":-0.6108},{"period":"1month","weight":-0.6897},{"period":"3month","weight":-0.6433},{"period":"6month","weight":-0.7174},{"period":"1year","weight":-0.6654},{"period":"ytd","weight":-0.4862}],"compareEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":0.0057},{"period":"3month","weight":0.0456},{"period":"6month","weight":0.2109},{"period":"1year","weight":0.1577},{"period":"ytd","weight":0.126}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Longeveron Inc于2014年10月9日成立为特拉华州有限责任公司，并于2014年12月15日获授权在佛罗里达州开展业务。该公司是一家临床阶段的生物技术公司，开发再生药物以满足未满足的医疗需求。该公司的主要研究产品是Lomecel-B牌MSCs，这是一种从年轻、健康的成年捐献者的骨髓中分离出来的同种异体药物信号传导细胞（MSC）治疗产品。Lomecel-B具有多种作用模式，包括促血管、促再生和抗炎机制，促进组织修复和愈合，在一系列疾病领域具有广泛的潜在应用前景。该公司目前正在开发三种临床适应症：左心发育不全综合征（HLHS）、衰老相关的虚弱和阿尔茨海默病（AD）。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.146765},{"month":2,"riseRate":0,"avgChangeRate":-0.052774},{"month":3,"riseRate":0.5,"avgChangeRate":0.19338},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.138428},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.132971},{"month":6,"riseRate":0.666667,"avgChangeRate":0.086991},{"month":7,"riseRate":0.5,"avgChangeRate":0.154004},{"month":8,"riseRate":0,"avgChangeRate":-0.277244},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.191007},{"month":10,"riseRate":0.4,"avgChangeRate":-0.0027},{"month":11,"riseRate":0.4,"avgChangeRate":1.291039},{"month":12,"riseRate":0,"avgChangeRate":-0.282059}],"exchange":"NASDAQ","name":"Longeveron Inc","nameEN":"Longeveron Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Longeveron Inc(LGVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Longeveron Inc(LGVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Longeveron Inc,LGVN,Longeveron Inc股票,Longeveron Inc股票老虎,Longeveron Inc股票老虎国际,Longeveron Inc行情,Longeveron Inc股票行情,Longeveron Inc股价,Longeveron Inc股市,Longeveron Inc股票价格,Longeveron Inc股票交易,Longeveron Inc股票购买,Longeveron Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Longeveron Inc(LGVN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Longeveron Inc(LGVN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}